<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00687011</url>
  </required_header>
  <id_info>
    <org_study_id>P04594</org_study_id>
    <nct_id>NCT00687011</nct_id>
  </id_info>
  <brief_title>Palonosetron Plus Dexamethasone in Moderately Emetogenic Chemotherapy Induced Nausea and Vomiting (Study P04594)</brief_title>
  <official_title>Open-label Clinical Trial to Assess the Efficacy, Tolerability and Safety of a Single IV Dose of Palonosetron 0.25 mg + Dexamethasone IV in the Prevention of Moderately Emetogenic Chemotherapy-induced Nausea and Vomit (CINV).</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if a single intravenous (IV) dose of palonosetron
      0.25 mg plus a single IV dose of dexamethasone 8 mg is effective to prevent nausea and
      vomiting induced by moderately emetogenic chemotherapy in subjects with cancer.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 10, 2006</start_date>
  <completion_date type="Actual">October 27, 2008</completion_date>
  <primary_completion_date type="Actual">October 27, 2008</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of patients having achieved complete response (CR), defined as no emetic episodes and no rescue medication.</measure>
    <time_frame>During 24 hours after administration of chemotherapy.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients who achieved a CR and of those who achieved complete control; Number of emetic episodes; Time to first emetic episode, to administration and need for rescue therapy; and to treatment failure</measure>
    <time_frame>Days 1 to 5 at different time intervals for each secondary outcome.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severity of nausea; Patient global satisfaction; Quality of life questionnaire</measure>
    <time_frame>Days 1 to 5 at different time intervals for each secondary outcome.</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">118</enrollment>
  <condition>Neoplasms</condition>
  <condition>Nausea</condition>
  <condition>Vomiting</condition>
  <arm_group>
    <arm_group_label>Palonosetron-dexamethasone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Palonosetron and Dexamethasone</intervention_name>
    <description>0.25 mg IV single dose, 30 minutes prior to the administration of the major chemotherapeutic agent, plus single IV dose of dexamethasone 8 mg administered 15 minutes before chemotherapy (in the event of a shortage of IV dexamethasone, a single oral dose of dexamethasone 20 mg or a single IV dose of methylprednisolone 125 mg could be administered).</description>
    <arm_group_label>Palonosetron-dexamethasone</arm_group_label>
    <other_name>SCH 734291</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female, &gt;= 18 years of age.

          -  Histologically or cytologically confirmed malignant disease.

          -  Naive or non-naive to chemotherapy.

          -  Karnofsky index &gt;= 70%.

          -  Scheduled to receive a single dose of at least one of the following agents
             administered on Study Day 1: any dose of Dactynomicin, Carboplatin, Epirubicin,
             Idarubicin, Ifosfamide, Irinotecan, Lomustine; or Methotrexate &gt;250 mg/m^2, or
             Cyclophosphamide &lt;=1500 mg/m^2, or Mitoxantrone &lt;15 mg/m^2, or Doxorubicin &gt;= 20
             mg/m^2, or Citarabin &gt; 1g/m^2, Melphalan &gt; 50 mg/m^2 , oxaliplatin &gt; 75 mg/m^2
             administered over 1 to 4 hours. The administration of the major chemotherapeutic agent
             (which is the most emetogenic agent according to the classification of Hesketh, et
             al., The Oncologist 1999, 4: 191-196) defined Study Day 1 and administration of this
             agent should not extend beyond 4 hours.

          -  Provided signed written informed consent.

          -  Females of childbearing potential must be using reliable contraceptive measures with a
             negative pregnancy test at the pre-treatment visit.

          -  If a patient had a known hepatic, renal or cardiovascular impairment and is scheduled
             to receive the above mentioned chemotherapeutic agents, he/she could be enrolled in
             this study at the discretion of the investigator.

          -  If a patient had experienced at maximum mild nausea following any previous
             chemotherapy regimen, he/she could be enrolled in this study at the discretion of the
             investigator.

        Exclusion Criteria:

          -  Unable to understand or cooperate with the study procedures.

          -  Received any investigational drugs within 30 days before study entry.

          -  Received any drug with potential anti-emetic efficacy within 24 hours of the start of
             treatment or will be scheduled to receive until Study Day 5 including 5-HT3 receptor
             antagonists, metoclopramide, phenothiazine anti-emetics (including prochlorperazine,
             thiethylperazine and perphenazine), scopolamine, diphenhydramine, chlorpheniramine
             maleate, trimethobenzamide, all benzodiazepines except temazepam or triazolam used
             once nightly for sleep, haloperidol, droperidol, tetrahydrocannabinol, or nabilone,
             any corticosteroid including dexamethasone, hydrocortisone, methylprednisolone,
             prednisone (excluding topical or inhaled preparations).

          -  Seizure disorder requiring anticonvulsant medication unless clinically stable and free
             of seizure activity.

          -  Experienced any vomiting, retching, or NCI Common Toxicity Criteria grade 2 or 3
             nausea in the 24 hours preceding chemotherapy.

          -  Ongoing vomiting from any organic etiology.

          -  Experienced nausea (moderate or severe) or vomiting following any previous
             chemotherapy. At the discretion of the investigator, a patient who experienced at
             maximum mild nausea following any previous chemotherapy might not be excluded from
             this study.

          -  Scheduled to receive any dose of cisplatin, carmustine, hexametilamine, dacarbazine,
             Mecloretamine, Streptozotocin, Procarbazine o Cyclophosphamide &gt; 1500 mg/m^2 or any
             other chemotherapeutic agent with an emetogenicity level 5 according to the
             classification of NCCN Guidelines v1 2005 during Study Days 2-6.

          -  Known contraindication to 5-HT3 receptor antagonists.

          -  Scheduled to receive radiotherapy of the upper abdomen or cranium during Study Day
             2-6.

          -  QTc &gt; 500 msec at baseline.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <removed_countries>
    <country>Mexico</country>
  </removed_countries>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 27, 2008</study_first_submitted>
  <study_first_submitted_qc>May 29, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 30, 2008</study_first_posted>
  <last_update_submitted>May 12, 2017</last_update_submitted>
  <last_update_submitted_qc>May 12, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 15, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Antiemetic</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nausea</mesh_term>
    <mesh_term>Vomiting</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>BB 1101</mesh_term>
    <mesh_term>Palonosetron</mesh_term>
    <mesh_term>Emetics</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf
http://engagezone.msd.com/ds_documentation.php</ipd_description>
  </patient_data>
  <study_docs>
    <study_doc>
      <doc_type>CSR Synopsis</doc_type>
      <doc_url>http://www.merck.com/clinical-trials/policies-perspectives.html</doc_url>
    </study_doc>
  </study_docs>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

